comscore Ex-U.S. vaccine chief fired over sexual harassment allegations | Honolulu Star-Advertiser
Top News

Ex-U.S. vaccine chief fired over sexual harassment allegations

  • ASSOCIATED PRESS
                                Dr. Moncef Slaoui, chief science adviser to Operation Warp Speed, the U.S. effort to rapidly develop COVID-19 vaccines, spoke, Jan. 12, during a news conference in Washington. GlaxoSmithKline said Slaoui has been fired as chair of a medical research company over sexual harassment allegations.

    ASSOCIATED PRESS

    Dr. Moncef Slaoui, chief science adviser to Operation Warp Speed, the U.S. effort to rapidly develop COVID-19 vaccines, spoke, Jan. 12, during a news conference in Washington. GlaxoSmithKline said Slaoui has been fired as chair of a medical research company over sexual harassment allegations.

The former chief science adviser for the U.S. effort to rapidly develop COVID-19 vaccines has been fired from the board of directors of a medical research company over sexual harassment allegations, drugmaker GlaxoSmithKline said today.

The company said it is firing Moncef Slaoui from his position as board chair at Galvani Bioelectronics, effective immediately, after its investigation substantiated a complaint about his conduct toward an employee “several years ago” when Slaoui worked for the drugmaker.

GlaxoSmithKline is a majority shareholder of Galvani Bioelectronics.

Slaoui served as chief science adviser to Operation Warp Speed, which was launched under the Trump administration to develop vaccines and treatments for COVID-19.

Slaoui could not be reached today for comment. Emails to the recently launched Centessa Pharmaceuticals, where Slaoui is listed as chief scientific officer, and Medicxi, where he is listed as a partner, were not immediately returned.

GlaxoSmithKline said its investigation began after it received a letter in February outlining the allegations of “sexual harassment and inappropriate conduct.” It said that Slaoui’s conduct was “unacceptable” and an “abuse of his leadership position.” It did not provide further details.

Slaoui spent nearly 30 years at GlaxoSmithKline, holding roles including chair of pharmaceutical research and development, chair of global research and development and board member, according to Centessa’s website.

Click here to see our full coverage of the coronavirus outbreak. Submit your coronavirus news tip.

Be the first to know
Get web push notifications from Star-Advertiser when the next breaking story happens — it's FREE! You just need a supported web browser.
Subscribe for this feature
Comments (3)

By participating in online discussions you acknowledge that you have agreed to the Terms of Service. An insightful discussion of ideas and viewpoints is encouraged, but comments must be civil and in good taste, with no personal attacks. If your comments are inappropriate, you may be banned from posting. Report comments if you believe they do not follow our guidelines.

Having trouble with comments? Learn more here.

Scroll Up